
Registration is open for the 13th COMy Congress! • May 13-16, 2027 • Paris, France + Online The biggest questions in myeloma, discussed live. Register on-site at the early bird rate ⬎ comy.cme-congresses.com/regi… @Mohty_EBMT

The World Congress on Controversies in Multiple Myeloma (COMy)

Registration is open for the 13th COMy Congress! • May 13-16, 2027 • Paris, France + Online The biggest questions in myeloma, discussed live. Register on-site at the early bird rate ⬎ comy.cme-congresses.com/regi… @Mohty_EBMT

🎙️ What to Expect in Multiple Myeloma at #ASH26? Looking at the abstracts already available, one message is clear: we are witnessing a fundamental transformation in how we treat myeloma. We are moving beyond conventional combinations of: • Proteasome inhibitors • Immunomodulatory agents • Monoclonal antibodies Toward a landscape increasingly dominated by: • T-cell redirection • Multi-antigen targeting • Highly personalized immunotherapy The question is no longer just: How deep a response can we achieve? It is becoming: How do we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients' quality of life? In our new podcast, we highlight 5 major developments we believe deserve particular attention at #ASH26 in New Orleans. 🎧 Listen here: on.soundcloud.com/PR2CKPiJ8h… #MultipleMyeloma @Mohty_EBMT

What to Expect in Multiple Myeloma at #ASH2026 by @TheIACH soundcloud.com/cme-congresse…

🔴 We are Live! Making sense of treatment options at first relapse with Joseph Mikhael Join the webinar → @jmikhaelmd @Mohty_EBMT

🩺 CAR-T or bispecific? How do we approach early relapse? What comes after BCMA-directed therapy? Real-life decision making in the era of bispecifics! Join Mohamad Mohty and Douglas W. Sborov for interactive clinical cases, live polling & panel discussion. 📅 Dec 11 | New Orleans + Virtual 👉 Register: ash-symposium.iach.org/#regi… #MultipleMyeloma #IACH @Mohty_EBMT

→ Tune in to the latest IACH News podcast: OPTIMUM/MUKnine: Can intensified, risk-adapted therapy overcome high-risk multiple myeloma? ⭣ on.soundcloud.com/9B5qJsit0R… Click for the abstract ⬎ pubmed.ncbi.nlm.nih.gov/4270… @Mohty_EBMT

👂Hear the latest IACH news in French: Vers un traitement précoce du myélome multiple indolent ? ⬇️⬇️ on.soundcloud.com/D0QhEUPAYr… Click for the abstract👇 pubmed.ncbi.nlm.nih.gov/4272… @Mohty_EBMT

🩺 What does the growing use of anti-BCMA bispecific mean for everyday clinical practice? Find out at the IACH Symposium at ASH 2026. This focused program will move beyond the clinical trial data to explore the questions that matter in practice — when to use bispecific, how to sequence them, how to manage toxicity and infections, and what to do when patients relapse after BCMA-directed therapy. 📅 December 11 | 07:00–10:00AM CT 💻 In person + virtual 👉 Register: ash-symposium.iach.org/#regi… This activity is approved for AMA PRA Category 1 𝘊𝘳𝘦𝘥𝘪𝘵™ #MultipleMyeloma #IACH #Hematology

What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma? My best guess below... thanks @TheIACH @Mohty_EBMT for the invitation!
🔴 We are Live! CAR-T: Optimizing Bridging Therapy and Early Response with Rahul Banerjee Join the webinar → us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT

Join us for the upcoming IACH Multiple Myeloma Masterclass Series: Making sense of treatment options at first relapse with Joseph Mikhael Thursday, November 12 6 pm CET • 12 pm NY Register now for free👇 us06web.zoom.us/webinar/regi… @jmikhaelmd @Mohty_EBMT

🎥Now streaming: #COMy2026 ON-DEMAND Rewatch the sessions everyone’s talking about - exclusively for registered attendees ⤵️ comy.cme-congresses.com/prog… ➡️ Available until July 31st @Mohty_EBMT

🎥 The #COMy2026 On-Demand Library now includes highlights from Richard @TheIACH AI Doctor. Quick summaries and key takeaways from expert discussions in multiple myeloma, all in one place! 👉 Visit the on-demand library: comy.cme-congresses.com/prog… @Mohty_EBMT

🔴 We are Live! CAR-T: Optimizing Bridging Therapy and Early Response with Rahul Banerjee Join the webinar → us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT

📅 Coming up next month in New Orleans! Join IACH on December 11 for a focused symposium on anti-BCMA bispecific antibodies in multiple myeloma - from the latest clinical evidence to real-world implementation and practical clinical cases. Free In person + virtual registration 🔗 ash-symposium.iach.org/#regi… @Mohty_EBMT @ElenaZamagni @mvmateos @NBahlis #MultipleMyeloma #Hematology

📣 Join IACH at ASH 2026! Explore the evolving role of anti-BCMA bispecific antibodies in multiple myeloma with an international expert faculty. From biology and clinical data to real-world implementation, toxicity management and interactive clinical cases. 📅 December 11 | 07:00–10:00AM CT 📍 In person + virtual 👉 Register now: ash-symposium.iach.org/#regi… This activity is approved for AMA PRA Category 1 CreditTM @Mohty_EBMT @NBahlis @mvmateos @ElenaZamagni #MultipleMyeloma #IACH

Join us for the upcoming IACH Multiple Myeloma Masterclass Series: 𝗖𝗔𝗥-𝗧: 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗘𝗮𝗿𝗹𝘆 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 with Rahul Banerjee Tuesday, November 3 6 pm CET • 12 pm NY Register now for free👇 us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT